Volume 13, Issue 3 (Summer-In Press 2025)
Iran J Health Sci 2025, 13(3): 0-0 |
Back to browse issues page
Ethics code: Not applicable
Clinical trials code: Not applicable
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Addissouky T. Enhancing Tertiary Prevention in Liver Disease: Integrating Bioartificial Liver Systems and Organoid Technologies for Advanced Therapeutic Support. Iran J Health Sci 2025; 13 (3)
URL: http://jhs.mazums.ac.ir/article-1-1015-en.html
URL: http://jhs.mazums.ac.ir/article-1-1015-en.html
New burg El-Arab Hospital, Ministry of Health, Alexandria, Egypt. , tedesoky@gmail.com
Abstract: (35 Views)
Background: Liver diseases remain a major global health challenge, with limited therapeutic options primarily due to donor organ scarcity and inadequate preclinical models. Bioartificial liver (BAL) support systems and liver organoids have emerged as innovative technologies for liver disease modeling, drug screening, and therapeutic development. However, comparative evaluation of their functionalities and clinical applicability is needed to guide future research and clinical translation.
Methods: A narrative literature review was conducted covering publications from January 2015 to May 2024. Searches were performed in PubMed, Scopus, Web of Science, and Embase using keywords related to “bioartificial liver,” “liver organoids,” “drug screening,” and “liver disease modeling.” Inclusion criteria encompassed peer-reviewed original research, clinical trials, and reviews focusing on BAL systems and liver organoids applied to liver disease and drug development. The PICO framework targeted human-relevant liver models (Population), BAL and organoid technologies (Intervention), conventional models or comparative technologies (Comparison), and outcomes related to metabolic functionality and drug screening efficacy (Outcome).
Results: BAL systems primarily provide extracorporeal detoxification and metabolic support, with clinical trials demonstrating transient liver function improvement but limited long-term efficacy. Advances in cell source optimization, notably iPSC-derived hepatocytes, and perfusion bioreactors have improved viability and function. Liver organoids, derived from stem cells or adult tissues, exhibit higher fidelity in replicating liver metabolic pathways, including albumin synthesis and bile acid metabolism, enabling superior predictive accuracy in drug toxicity screening and personalized disease modeling. Genetic engineering enhances organoid applicability for precision medicine. However, organoid scalability and vascularization remain challenges.
Conclusions: While BAL systems offer valuable temporary liver support, liver organoids outperform BAL in metabolic functionality and drug screening applications. Future research should focus on integrating organoids with BAL platforms, advancing bioreactor design, and standardizing protocols to accelerate clinical translation and personalized therapeutics development.
Methods: A narrative literature review was conducted covering publications from January 2015 to May 2024. Searches were performed in PubMed, Scopus, Web of Science, and Embase using keywords related to “bioartificial liver,” “liver organoids,” “drug screening,” and “liver disease modeling.” Inclusion criteria encompassed peer-reviewed original research, clinical trials, and reviews focusing on BAL systems and liver organoids applied to liver disease and drug development. The PICO framework targeted human-relevant liver models (Population), BAL and organoid technologies (Intervention), conventional models or comparative technologies (Comparison), and outcomes related to metabolic functionality and drug screening efficacy (Outcome).
Results: BAL systems primarily provide extracorporeal detoxification and metabolic support, with clinical trials demonstrating transient liver function improvement but limited long-term efficacy. Advances in cell source optimization, notably iPSC-derived hepatocytes, and perfusion bioreactors have improved viability and function. Liver organoids, derived from stem cells or adult tissues, exhibit higher fidelity in replicating liver metabolic pathways, including albumin synthesis and bile acid metabolism, enabling superior predictive accuracy in drug toxicity screening and personalized disease modeling. Genetic engineering enhances organoid applicability for precision medicine. However, organoid scalability and vascularization remain challenges.
Conclusions: While BAL systems offer valuable temporary liver support, liver organoids outperform BAL in metabolic functionality and drug screening applications. Future research should focus on integrating organoids with BAL platforms, advancing bioreactor design, and standardizing protocols to accelerate clinical translation and personalized therapeutics development.
Keywords: Liver Diseases, Bioartificial Organs, Organoids, Liver Regeneration, Drug, Screening Assays, Pharmacological
Type of Study: Review Article |
Subject:
Health
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
